Dose-modified Emapalumab and Ruxolitinib for Hemophagocytic Lymphohistiocytosis

This clinical trial investigates a new treatment method for individuals with active Hemophagocytic Lymphohistiocytosis (HLH), a serious disorder where the immune system becomes overly active and causes harmful inflammation. HLH is rare but can be fatal if not managed correctly. The study focuses on patients experiencing this condition and aims to provide insights into more effective treatment options. By exploring this new treatment approach, the study hopes to enhance patient outcomes and offer better management strategies for HLH. Participants in this trial will receive a combination of two medications designed to address the excessive immune activity in HLH. Emapalumab, a monoclonal antibody, will be given at a reduced dose to minimize side effects, and it works by blocking a protein that drives the immune overreaction. Ruxolitinib, another medication involved, will be administered at a higher dose to boost its effectiveness in reducing inflammation by targeting specific pathways in the immune system. The study is conducted across multiple healthcare centers, where patients will be monitored over time to evaluate the safety and effectiveness of this treatment combination.